Effect of subanesthetic dose of esketamine on postoperative depression and anxiety in kidney transplantation patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046136

Enrollment

Unknown

Registered

2021-05-04

Start date

2021-06-01

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

control group:Normal saline 10ml

esketamine group I:esketamine0.2mg/kg

esketamine group II:esketamine0.4mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients who planned to receive kidney transplantation under general anesthesia; 2.Aged 18 to 65 years, ASA class II-III, male or female; 3.Preoperative hospital anxiety and depression scale (HADS) score of depression and/or anxiety status >= 11 points; 4.Signed informed consent for anesthesia and clinical trial.

Exclusion criteria

Exclusion criteria: 1. Unable to cooperate with the evaluation; 2. Preoperative cognitive dysfunction; 3. Allergic to the drugs used in this study; 4. Patients with intraoperative blood loss of > 400ml or requiring intraoperative blood transfusion; 5. The kidney transplant failed; 6. Combined with important organ diseases except kidney; 7. With history of mental illness; 8. With history of drug abuse.

Design outcomes

Primary

Measure	Time frame
Hospital Anxiety and Depression Scale;	—

Secondary

Measure	Time frame
visual analogue scale;	—

Countries

China

Contacts

Public ContactWang Feng

Affiliated Hospital of Guizhou Medical University

294676396@qq.com+86 15508516196

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026